Metastatic breast cancer trials in Netherlands

In Netherlands 20 Also abroad 610

20 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Where
Geleen, Maastricht, Nijmegen, 's-Gravenhage
Age
18 years and over
People
540 worldwide
Run by
Relay Therapeutics, Inc.
See details and how to joinNCT06982521 · EU 2025-523083-21-00
Phase 1Taking people
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
Where
Leiden
Age
18 years and over
People
194 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07604571
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Amsterdam, Groningen, Nijmegen, Rotterdam, Utrecht
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 1Taking people
A clinical trial to learn about the effects of IEV407 when given alone or with endocrine therapy in people with advanced breast cancer
Where
Leiden
Age
18 years and over
People
40 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-522707-26-00 · EU 2025-522707-26-00
Phase 3Taking people
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Where
Hilversum, Schiedam, Utrecht
Age
18 years and over
People
400 worldwide
Run by
Pfizer
See details and how to joinNCT07062965 · EU 2025-520566-22-00
Phase 3Taking people
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Where
Amersfoort, Amsterdam, Arnhem, Breda, Eindhoven, Maastricht, Zwolle
Age
18 years and over
People
1,200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06312176 · EU 2023-504918-29-00
Phase 3Taking people
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Where
Amsterdam, Apeldoorn, Maastricht
Age
18 years and over
People
1,000 worldwide
Run by
Olema Pharmaceuticals, Inc.
See details and how to joinNCT07085767 · EU 2025-522873-12-00
Phase 2Taking people
COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study
Where
Alkmaar, Amsterdam, Arnhem, Deventer, Goes, Groningen, Utrecht
Age
18 years and over
People
56
Run by
The Netherlands Cancer Institute
See details and how to joinNCT05301881
No phaseTaking people
EORTC Metastatic Breast Cancer Module Development
Where
Amsterdam
Age
18 years and over
People
568 worldwide
Run by
University of Leeds
See details and how to joinNCT07806266
Phase 1Taking people
A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers
Where
Groningen
Age
18 years to 100 years
People
36
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07117214
Phase 1Taking people
A phase I study of [68Ga]Ga-DWJ155 in patients with advanced breast and NSCLC cancers
Where
Groningen
Age
18 years and over
People
36
Run by
Novartis Pharma AG
See details and how to join2024-517746-34-00 · EU 2024-517746-34-00
Phase 2Taking people
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
Where
Amsterdam
Age
18 years and over
People
200 worldwide
Run by
MedSIR
See details and how to joinNCT06486883 · EU 2024-512360-55-00
Phase 1/2Taking people
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Where
Amsterdam, Rotterdam
Age
18 years and over
People
880 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT05768139 · EU 2023-504807-94-00
Phase 3Taking people
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Where
Amsterdam, Breda, Leeuwarden, Leiderdorp, Maastricht, Nijmen, 's-Gravenhage, Tilburg, Uden
Age
18 years and over
People
250 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT05950945 · EU 2023-505616-38-00
Phase 1Taking people
Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.
Where
Nijmegen, Utrecht
Age
18 years and over
People
76 worldwide
Run by
Novartis Pharma AG
See details and how to join2023-510356-23-00 · EU 2023-510356-23-00
Phase 2Taking people
Basket Study for Oligo-metastatic Breast Cancer
Where
Amsterdam
Age
18 years and over
People
72
Run by
The Netherlands Cancer Institute
See details and how to joinNCT05982678
Phase 2Taking people
FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test
Where
Groningen, Leiden, Rotterdam
Age
18 years and over
People
66
Run by
Erasmus Medical Center
See details and how to joinNCT06193525
Phase 2Taking people
NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial
Where
Amsterdam
Age
18 years and over
People
60
Run by
The Netherlands Cancer Institute
See details and how to joinNCT06342037
No phaseTaking people
Southeast Netherlands Advanced Metastatic Breast Cancer Registry
Where
Maastricht
Age
18 years and over
People
7,000
Run by
Academisch Ziekenhuis Maastricht
See details and how to joinNCT03577197
Phase 2Taking people
Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients
Where
Amsterdam
Age
18 years and over
People
52
Run by
The Netherlands Cancer Institute
See details and how to joinNCT04159818 · EU 2024-513217-12-00